Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report (Q34486831)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report (English)

1 reference

Europe PubMed Central

2 August 2017

3 references

13 March 2019

24 March 2019

12 November 2019

0 references

pathologic fracture

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

organic compound, having C-P covalent bound

1 reference

12 November 2019

bone density conservation agents

1 reference

16 July 2021

object named as

N Napoli

5

0 references

object named as

C Cooper

8

0 references

author name string

R Rizzoli

1

1 reference

Europe PubMed Central

2 August 2017

K Akesson

2

1 reference

Europe PubMed Central

2 August 2017

M Bouxsein

3

1 reference

Europe PubMed Central

2 August 2017

J A Kanis

4

1 reference

Europe PubMed Central

2 August 2017

S Papapoulos

6

1 reference

Europe PubMed Central

2 August 2017

J-Y Reginster

7

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

18 November 2010

1 reference

Europe PubMed Central

2 August 2017

1 February 2011

4 references

13 March 2019

24 March 2019

12 November 2019

16 July 2021

Osteoporosis International

5 references

Europe PubMed Central

2 August 2017

13 March 2019

24 March 2019

12 November 2019

16 July 2021

22

1 reference

Europe PubMed Central

2 August 2017

373-390

1 reference

Europe PubMed Central

2 August 2017

2

1 reference

Europe PubMed Central

2 August 2017

copyright license

Creative Commons Attribution-NonCommercial 4.0 International

1 reference

Europe PubMed Central

16 July 2021

https://scigraph.springernature.com/pub.10.1007/s00198-010-1453-5

0 references

Atypical femoral diaphyseal and subtrochanteric fractures and their association with bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Healing of non-displaced fractures produced by fatigue loading of the mouse ulna.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Bisphosphonates in oncology: evidence for the prevention of skeletal events in patients with bone metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Atraumatic bilateral femur fracture in long-term bisphosphonate use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Alendronate-related femoral diaphysis fracture--what should be done to predict and prevent subsequent fracture of the contralateral side?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Case reports: two femoral insufficiency fractures after long-term alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Spectroscopic markers of bone quality in alendronate-treated postmenopausal women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Severely suppressed bone turnover and atypical skeletal fragility

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Alendronate reduces bone toughness of ribs without significantly increasing microdamage accumulation in dogs following 3 years of daily treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Low-energy femoral shaft fractures associated with alendronate use.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Zoledronic acid and clinical fractures and mortality after hip fracture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Modern therapy for Paget's disease of bone: focus on bisphosphonates

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Severely suppressed bone turnover: a potential complication of alendronate therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Imaging studies for diagnosing stress and insufficiency fractures

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Unstable intertrochanteric/subtrochanteric fractures of the femur.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

6 July 2018

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Treatment of bone metastases and bone pain with bisphosphonates

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendronate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Fragility fractures of the hip and femur: incidence and patient characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral femoral insuffiency fractures treated with inflatable intramedullary nails: a case report.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy--a case report

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Unusual mid-shaft fractures during long-term bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Spontaneous femoral shaft fracture after long-term alendronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral atypical femoral diaphyseal fractures in a patient treated with alendronate sodium

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Principles of Bone Biomechanics

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Three years of alendronate treatment results in similar levels of vertebral microdamage as after one year of treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

1 reference

https://api.crossref.org/works/10.1007%2FS00198-010-1453-5

21 January 2018

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

27 October 2018

Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3020314

27 October 2018

Extramedullary fixation of 107 subtrochanteric fractures: a randomized multicenter trial of the Medoff sliding plate versus 3 other screw-plate systems

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intervention thresholds for osteoporosis in the UK

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Looking back: developments in our understanding of the occurrence, aetiology and prognosis of osteoporosis over the last 50 years

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppressed Bone Turnover during Alendronate Therapy for High-Turnover Osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

More on atypical fractures of the femoral diaphysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-energy femoral fractures associated with long-term bisphosphonate use in a rehabilitation setting: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric Femoral Insufficiency Fracture in Woman on Bisphosphonate Therapy for Glucocorticoid-Induced Osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric fractures

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Subtrochanteric fractures of the femur

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lower extremity stress fractures during intermittent cyclical etidronate treatment for osteoporosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21085935

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00198-010-1453-5

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34486831&oldid=1614830879"